Literature DB >> 17021403

Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.

Constance A Griffin1, Peter Burger, Laura Morsberger, Raluca Yonescu, Sharon Swierczynski, Jon D Weingart, Kathleen M Murphy.   

Abstract

Deletions of portions of chromosomes 1p and 19q are closely associated with the oligodendroglioma histologic phenotype. In most cases, 1p and 19q are codeleted, yet the mechanism of dual loss is unexplained. We report 5 cases (World Health Organization grade III) in which metaphase cytogenetics identified a derivative chromosome consisting of what appears to be the whole arms of 1q and 19p forming a der(1;19)(q10;p10). Metaphase fluorescent in situ hybridization (FISH) confirmed the derivative chromosome was composed of 1q and 19p material in 3 cases; in 2 cases with few metaphases, FISH confirmed 19p material on the derivative chromosome. In all cases, interphase FISH showed net loss of 1p and 19q in 77% to 92% of cells, and microsatellite studies were consistent with 1p and 19q loss. We hypothesize the following: occurrence of a balanced whole-arm translocation between chromosomes 1 and 19 forming 2 derivative chromosomes, one composed of 1q and 19p, the other of 1p and 19q. Subsequent loss of the der(1;19)(p10;q10) then results in the simultaneous 1p and 19q loss observed in oligodendroglioma with retention of the der(1;19)(q10;p10) seen in these cases.

Entities:  

Mesh:

Year:  2006        PMID: 17021403     DOI: 10.1097/01.jnen.0000235122.98052.8f

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  72 in total

Review 1.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

2.  Oligodendrogliomas: a short history of clinical developments.

Authors:  Martin J van den Bent
Journal:  CNS Oncol       Date:  2015

3.  Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults.

Authors:  Erik Vassella; Istvan Vajtai; Nora Bandi; Marlene Arnold; Verena Kocher; Luigi Mariani
Journal:  J Neurooncol       Date:  2010-12-22       Impact factor: 4.130

4.  Mutations in CIC and FUBP1 contribute to human oligodendroglioma.

Authors:  Chetan Bettegowda; Nishant Agrawal; Yuchen Jiao; Mark Sausen; Laura D Wood; Ralph H Hruban; Fausto J Rodriguez; Daniel P Cahill; Roger McLendon; Gregory Riggins; Victor E Velculescu; Sueli Mieko Oba-Shinjo; Suely Kazue Nagahashi Marie; Bert Vogelstein; Darell Bigner; Hai Yan; Nickolas Papadopoulos; Kenneth W Kinzler
Journal:  Science       Date:  2011-08-04       Impact factor: 47.728

Review 5.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

6.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

7.  Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients.

Authors:  Fausto J Rodriguez; Tarik Tihan; Doris Lin; William McDonald; Janice Nigro; Burt Feuerstein; Sadhana Jackson; Kenneth Cohen; Peter C Burger
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

8.  Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.

Authors:  Fabio M Iwamoto; Linda Nicolardi; Alexis Demopoulos; Violetta Barbashina; Paulo Salazar; Marc Rosenblum; Adília Hormigo
Journal:  J Neurooncol       Date:  2008-03-15       Impact factor: 4.130

Review 9.  Management of low-grade glioma.

Authors:  Nader Pouratian; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

Review 10.  Molecular neuropathology of gliomas.

Authors:  Markus J Riemenschneider; Guido Reifenberger
Journal:  Int J Mol Sci       Date:  2009-01-07       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.